Loading…
Chinese biotech developing apoptosis-targeting cancer drugs, including approved CML drug olverembatinib and Bcl-2 inhibitor lisaftoclax.
Chinese biotech developing apoptosis-targeting cancer drugs, including approved CML drug olverembatinib and Bcl-2 inhibitor lisaftoclax.
Sells olverembatinib itself in China, and funds the rest of its pipeline partly from licence fees and milestone payments from larger pharma partners, with a loss-making profile typical of a company paying for late-stage trials. Hospitals in China are the buyers, with insurance reimbursement important for volumes.
In one line: A Chinese AbbVie-style apoptosis/oncology drug developer.
Moat: narrow (IP / patents, first-mover approval). Approved BCR-ABL inhibitor for drug-resistant CML with patent protection.
Headquarters: Suzhou, China · Founded: 2009 · Employees: 767
Size Ascentage Pharma Group International (6855.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.39B, the 507th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$29.28 on 6 Nov 2026.
Performance Over six months the shares fell 33.1%, against -17.1% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 70.3% over the last twelve months (peer median +14.7%); the operating margin is -220.0% (peer median 7.3%).
Valuation It trades at 15.5× enterprise value to sales against a peer median of 7.1× (4th most expensive of 19).
Capital Return on invested capital runs 155.4 points below its cost of capital (8.2% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$717M | HK$623M | HK$1.06B | HK$245M | HK$244M |
| Revenue growth | — | -41% | +333% | +1% | — |
| Gross profit | HK$597M | HK$493M | HK$940M | HK$126M | HK$147M |
| EBITDA | -HK$1.48B | -HK$1.22B | -HK$310M | -HK$900M | -HK$956M |
| Net income | -HK$1.64B | -HK$1.35B | -HK$440M | -HK$1.02B | -HK$1.03B |
| Free cash flow | -HK$1.58B | -HK$1.38B | -HK$213M | -HK$947M | -HK$1.08B |
| Capital expenditure | HK$22.2M | HK$29.9M | HK$26.3M | HK$62.8M | HK$276M |
| Total debt | n/a | HK$2.21B | HK$1.81B | HK$1.98B | HK$2.01B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Ascentage Pharma Group International 6855.HK | $1.39B | -33% | +70% | -220% | 15.5× | n/a |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 8.9× | -0.1% |
| InnoCare Pharma 9969.HK | $2.31B | -13% | +146% | 35% | 3.4× | 0.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6855.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.4% | -7.0% | 4th highest of 21 |
| 6-month return | -33.1% | -17.1% | 3rd lowest of 21 |
| Distance from 52-week high | -57.8% | -42.2% | 4th lowest of 21 |
| Revenue growth (TTM) | +70.3% | +14.7% | 3rd highest of 19 |
| Operating margin | -220.0% | 7.3% | 3rd lowest of 19 |
| EV / Sales | 15.5× | 7.1× | 4th most expensive of 19 |
| ROIC minus cost of capital | -155.4 pp | -4.1 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 5.2× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | 15.3× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 44.5× | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | 226.6× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 0.9× | -17.5% | +7.0% |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |